Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fasudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 8/20 | 0.98 |
| ▸ | ROCK1 known ✓ | Q13464 | 7/20 | 0.98 |
| ▸ | CCR2 | P41597 | 2/20 | 0.98 |
| ▸ | HTT | P42858 | 2/20 | 0.98 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.95 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.95 |
| ▸ | PRKD1 | Q15139 | 6/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.95 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.95 |
| ▸ | PRKCG | P05129 | 5/20 | 0.95 |
| ▸ | PRKCB | P05771 | 5/20 | 0.95 |
| ▸ | PRKCA | P17252 | 5/20 | 0.95 |
| ▸ | PRKCH | P24723 | 5/20 | 0.95 |
| ▸ | PRKCI | P41743 | 5/20 | 0.95 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.95 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.95 |
| ▸ | PRKACA | P17612 | 4/20 | 0.95 |
| ▸ | PRKACG | P22612 | 4/20 | 0.95 |
| ▸ | PRKACB | P22694 | 4/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fasudil SCHEMBL6269513 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL2154690 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL30064396 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL4725334 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL30084458 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL6032335 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL29351490 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL29393852 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL599053 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL317082 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087564-B1 | FASUDIL FOR USE IN METHODS OF TREATING ALZHEIMER'S DEMENTIA ASSOCIATED WANDERING | WOOLSEY PHARMACEUTICALS INC (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4654975-A1 | TREATMENT OF THE CHRONIC EFFECTS OF BRAIN INJURY USING RHO KINASE INHIBITORS | Woolsey Pharmaceuticals, Inc. (US) | 2025-12-03 | — | — | EP | claimed |
| EP-4125910-B1 | RHO KINASE INHIBITORS FOR TREATING FRONTOTEMPORAL DEMENTIA | WOOLSEY PHARMACEUTICALS INC (US) | 2025-11-12 | — | — | EP | claimed |
| EP-4616909-A2 | METHODS OF TREATING CORTICAL DEMENTIA ASSOCIATED WANDERING | Woolsey Pharmaceuticals, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4103187-B1 | FASUDIL FOR TREATING PSEUDOBULBAR AFFECT | WOOLSEY PHARMACEUTICALS INC (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250228868-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | WOOLSEY PHARMACEUTICALS, INC. (US) | 2025-07-17 | — | — | US | claimed |
| WO-2025101834-A1 | METHODS OF TREATING SPORADIC CEREBRAL SMALL VESSEL DISEASE | WOOLSEY PHARMACEUTICALS, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| US-12290522-B2 | Method of treating amyotrophic lateral sclerosis | WOOLSEY PHARMACEUTICALS, INC. (US) | 2025-05-06 | — | — | US | claimed |
| WO-2025024104-A2 | METHOD FOR REDUCING CAREGIVER BURDEN ASSOCIATED WITH ALZHEIMER'S DISEASE | WOOLSEY PHARMACEUTICALS, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| US-20240423998-A1 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | WOOLSEY PHARMACEUTICALS, INC. | 2024-12-26 | — | — | US | claimed |
| US-11865119-B2 | Methods of treating agitation and other dementia-associated behavioral symptoms | WOOLSEY PHARMACEUTICALS, INC. (US) | 2024-01-09 | — | — | US | claimed |
| US-11771704-B1 | Methods of using rho kinase inhibitors to treat alzheimer's disease | WOOLSEY PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | claimed |
| US-20230302011-A1 | METHODS OF USING RHO KINASE INHIBITORS TO TREAT ALZHEIMER'S DISEASE | WOOLSEY PHARMACEUTICALS, INC. | 2023-09-28 | — | — | US | claimed |
| WO-2023158789-A1 | ORAL FORMULATIONS OF FASUDIL WITH ION EXCHANGE RESIN | WOOLSEY PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| US-20230201219-A1 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | WOOLSEY PHARMACEUTICALS, INC. | 2023-06-29 | — | — | US | claimed |
| US-11666583-B2 | Methods of treating cortical dementia associated wandering | WOOLSEY PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | claimed |
| WO-2023097151-A1 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | WOOLSEY PHARMACEUTICALS, INC. (US) | 2023-06-01 | — | — | WO | claimed |
| US-20220125799-A1 | METHODS OF TREATING 4-REPEAT TAUOPATHIES | WOOLSEY PHARMACEUTICALS, INC. | 2022-04-28 | — | — | US | claimed |
| US-11311553-B1 | Methods of treating 4-repeat tauopathies | WOOLSEY PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | claimed |
| CN-113968841-A | Preparation method of fasudil hydrochloride hemihydrate | 合肥久诺医药科技有限公司 | 2022-01-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423998-A1 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885CCR2 2973/4885 |
| US-11666583-B2 | Methods of treating cortical dementia associated wandering | ROCK2, ROCK1, CDC42 | ROCK2 1/4885ROCK1 2/4885CCR2 2636/4885 |
| US-20230302011-A1 | METHODS OF USING RHO KINASE INHIBITORS TO TREAT ALZHEIMER'S DISEASE | CIT, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885CCR2 879/4885 |
| US-12290522-B2 | Method of treating amyotrophic lateral sclerosis | SMN1; SMN2, SOD1, TARDBP | ROCK2 3633/4885ROCK1 3811/4885CCR2 4698/4885 |
| US-11311553-B1 | Methods of treating 4-repeat tauopathies | MAPT, ROCK2, ROCK1 | ROCK2 2/4885ROCK1 3/4885CCR2 3546/4885 |
| US-11771704-B1 | Methods of using rho kinase inhibitors to treat alzheimer's disease | CIT, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885CCR2 914/4885 |
| US-11865119-B2 | Methods of treating agitation and other dementia-associated behavioral symptoms | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885CCR2 2973/4885 |
| US-20250228868-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, TARDBP | ROCK2 3633/4885ROCK1 3811/4885CCR2 4698/4885 |
| US-20230201219-A1 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885CCR2 2973/4885 |
| US-20220125799-A1 | METHODS OF TREATING 4-REPEAT TAUOPATHIES | MAPT, ROCK2, ROCK1 | ROCK2 2/4885ROCK1 3/4885CCR2 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.